Print Page   |   Contact Us   |   Sign In   |   Become a Member
Site Search
News from the Field
Blog Home All Blogs
Search all posts for:   

 

View all (22) posts »
 

New from the Field

Posted By Connections Editor, Thursday, June 16, 2016
BloodCenter of Wisconsin and San Diego Blood Bank Announce Collaborative Offering Called Celluvative
BloodCenter of Wisconsin and the San Diego Blood Bank have created a strategic partnership to accelerate advancements in research and patient care. [Celluvative]

GlycoMimetics’ GMI-1271 Receives FDA Fast Track Designation for Treatment of Acute Myeloid Leukemia
GlycoMimetics, Inc. announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and elderly patients aged 60 years or older with AML. [GlycoMimetics, Inc.]

Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress
Galena Biopharma, Inc. announced that combined safety data from the Company’s GALE-401 clinical trials were presented. [Press release from Galena Biopharma, Inc. discussing research presented at the European Hematology Association 21st Congress, Copenhagen]

Seattle Genetics Highlights Vadastuximab Talirine (SGN-CD33A) Data in Acute Myeloid Leukemia (AML) at the 21st Congress of the European Hematology Association
Seattle Genetics, Inc. highlighted data evaluating vadastuximab talirine in combination with hypomethylating agents in frontline patients with acute myeloid leukemia who had declined intensive therapy. [Press release from Seattle Genetics discussing research presented at the European Hematology Association 21st Congress, Copenhagen]

Celator Pharmaceuticals® Announces Positive Results in Patients with FLT3 Mutation from the Phase III Trial in High-Risk Acute Myeloid Leukemia
Celator Pharmaceuticals, Inc. announced positive response rate results in acute myeloid leukemia patients with FLT3 (FMS-like tyrosine kinase-3) mutation were presented. [Press release from Celator Pharmaceuticals, Inc. discussing research presented at the European Hematology Association 21st Congress, Copenhagen]

New Approach Could Make Bone Marrow Transplants Safer
Researchers developed a non-toxic transplantation procedure using antibodies to specifically target blood stem cells in mice, an approach they hope will make blood stem cell transplants for these patients far less toxic. [Press release from Harvard Stem Cell Institute discussing online prepublication in Nature Biotechnology]

This post has not been tagged.

Share |
Permalink | Comments (0)
 
Association Management Software Powered by YourMembership.com®  ::  Legal